<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432015</url>
  </required_header>
  <id_info>
    <org_study_id>GOA-NVM1</org_study_id>
    <nct_id>NCT01432015</nct_id>
  </id_info>
  <brief_title>Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting</brief_title>
  <official_title>A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nausea and vomiting are two of the more concerning adverse outcomes associated with
      chemotherapy in the treatment of gynecologic malignancies. In fact, nearly 90% of cancer
      patients develop chemotherapy induced nausea and vomiting (CINV) following treatment with
      carboplatin and paclitaxel. The successful control of chemotherapy induced nausea and
      vomiting (CINV) is thus, of paramount importance in ensuring optimal treatment and sustaining
      a cancer patient's quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have indicated that oral and intravenous anti-emetics are equivalent with regard to
      efficacy; when evaluating cost and convenience, the intravenous route may be preferable.
      Fosaprepitant, a water-soluble phosphoryl prodrug for aprepitant, is converted to aprepitant
      via phosphatases following intravenous administration. Given the rapid conversion of
      fosaprepitant to the active form (i.e., aprepitant), the two medications appear to provide a
      similarly effective antiemetic impact. Clinical reports have additionally suggested that
      fosaprepitant could be appropriate as an intravenous alternative to the oral aprepitant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Complete Response Rate</measure>
    <time_frame>13 months</time_frame>
    <description>no emetic episodes or rescue therapy following the initiation of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact on Daily Living Activities</measure>
    <time_frame>13 months</time_frame>
    <description>Proportion of patients reporting no impact on daily living activities following initiation of chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Uterine Cancer</condition>
  <arm_group>
    <arm_group_label>Fosaprepitant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Oral Placebo given on days 1-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. 100 cc of IV placebo administered on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosaprepitant</intervention_name>
    <description>Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications</description>
    <arm_group_label>Fosaprepitant</arm_group_label>
    <other_name>Emend IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>One pill administered on days 1-3 in conjunction with Fosaprepitant.</description>
    <arm_group_label>Fosaprepitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IV placebo</intervention_name>
    <description>100 cc of IV placebo administered on day in conjunction with Aprepitant</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female Gender

          -  Age &gt; 18 years

          -  A histologic diagnosis of stage III/IV gynecologic cancer (e.g., epithelial ovarian,
             fallopian tube, peritoneal cancer and uterine cancer).

          -  Subjects who will be treated with Taxol and Carboplatin as standard of care for a
             newly diagnosed gynecological cancer.

          -  Adequate bone marrow function as demonstrated by:

        Absolute neutrophil count (ANC) &gt; 1,500/μL; platelet count &gt; 100,000/μL; and hemoglobin &gt; 9
        g/dL • Adequate renal function demonstrated by: Serum creatinine of &lt; 1.5 x ULN or 24-hr
        measured urine creatinine clearance &gt; 60 mL/min for patients with serum creatinine &gt; 1.5 x
        ULN

        • Adequate hepatic function demonstrated by: Total bilirubin of &lt; 1.5 x ULN AST or ALT ≤
        2.5 x ULN

          -  EGOG status of &lt; 2: Postoperatively, patients demonstrate an ECOG score of 1 or 2.
             However, during the first cycle of chemotherapy, the patients' performance status
             improves to &lt; 1.

          -  Projected life expectancy of at least 3 months

          -  Ability to comply with the visit schedule and assessments required by the protocol

          -  Negative pregnancy test for women of childbearing potential

          -  Signed, IRB approved informed consent and HIPPA consent

        Exclusion Criteria:

          -  Subjects with a diagnosis of epithelial ovarian, fallopian tube or peritoneal cancers
             of low malignant potential (borderline carcinomas) are not eligible.

          -  Allergy or intolerance to 5HT3 or NK-1 antagonists and dexamethasone

          -  An episode of vomiting or retching within 24 hours before the start of the initial
             treatment with chemotherapy

          -  Subjects with concomitant malignancy or a previous malignancy within the past three
             (3) years (except non-melanoma skin cancer)

          -  Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental drug study.

          -  Screening clinical laboratory values of:

        ANC of &lt;1500/DL Platelet count of &lt;100,000/µL Total bilirubin of *1.5 mg/dL x ULN SGOT
        (AST) or SGPT (ALT) * 2.5 x ULN Serum creatinine of * 1.5 mg/dL Hemoglobin of * 9 gm/dL
        (may be transfused or receive a colony stimulating factor to maintain or exceed this level)

          -  EGOG status of &gt; 2

          -  Gastrointestinal obstruction or an active peptic ulcer

          -  Patients who are pregnant or breast feeding because aprepitant may be harmful to the
             developing fetus and newborn

          -  Known active HIV and viral hepatitis infections

          -  Inability to comply with study

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (see
             Appendix D)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Micha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Associates</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2011</study_first_posted>
  <results_first_submitted>April 29, 2015</results_first_submitted>
  <results_first_submitted_qc>May 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2015</results_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aprepitant</keyword>
  <keyword>fosaprepitant</keyword>
  <keyword>gynecologic cancer</keyword>
  <keyword>emesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fosaprepitant and Placebo</title>
          <description>Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy.Oral Placebo 125 mg given 1 hour prior to infusion of chemotherapy on day 1 and oral Placebo 80 mg on day 2 and day 3. Patient will receive standard pre-medications on day 1</description>
        </group>
        <group group_id="P2">
          <title>Aprepitant and Placebo</title>
          <description>Aprepitant is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) with Intravenous Placebo on day 1 and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications on day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fosaprepitant Including Placebo</title>
          <description>Fosaprepitant (EMEND™) for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy.Oral Placebo 125 mg given 1 hour prior to infusion of chemotherapy on day 1 and oral Placebo 80 mg on day 2 and day 3.Patient will receive standard pre-medications on day 1
Aprepitant (EMEND™) is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3
fosaprepitant including placebo: Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications</description>
        </group>
        <group group_id="B2">
          <title>Aprepitant Including Placebo</title>
          <description>Aprepitant (EMEND™) is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) with Intravenous Placebo and 80 mg orally once daily in the morning on Days 2 and 3 with Placebo Intravenously on day 1. patient will receive standard pre-medications on day 1.
aprepitant including placebo: Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Impact on Daily Living Activities</title>
        <description>Proportion of patients reporting no impact on daily living activities following initiation of chemotherapy</description>
        <time_frame>13 months</time_frame>
        <population>Study participants included adult, female patients with a histologically confirmed, newly diagnosed gynecologic cancer (e.g., epithelial ovarian, fallopian tube, primary peritoneal cancer or uterine cancer).</population>
        <group_list>
          <group group_id="O1">
            <title>Fosaprepitant Including Placebo</title>
            <description>Fosaprepitant (EMEND™) for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy.Oral Placebo 125 mg given 1 hour prior to infusion of chemotherapy on day 1 and oral Placebo 80 mg on day 2 and day 3.Patient will receive standard pre-medications on day 1
Aprepitant (EMEND™) is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3
fosaprepitant including placebo: Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications</description>
          </group>
          <group group_id="O2">
            <title>Aprepitant Including Placebo</title>
            <description>Aprepitant (EMEND™) is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) with Intravenous Placebo and 80 mg orally once daily in the morning on Days 2 and 3 with Placebo Intravenously on day 1. patient will receive standard pre-medications on day 1.
aprepitant including placebo: Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications</description>
          </group>
        </group_list>
        <measure>
          <title>Impact on Daily Living Activities</title>
          <description>Proportion of patients reporting no impact on daily living activities following initiation of chemotherapy</description>
          <population>Study participants included adult, female patients with a histologically confirmed, newly diagnosed gynecologic cancer (e.g., epithelial ovarian, fallopian tube, primary peritoneal cancer or uterine cancer).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Complete Response Rate</title>
        <description>no emetic episodes or rescue therapy following the initiation of chemotherapy</description>
        <time_frame>13 months</time_frame>
        <population>Study participants included adult, female patients with a histologically confirmed, newly diagnosed gynecologic cancer (e.g., epithelial ovarian, fallopian tube, primary peritoneal cancer or uterine cancer).</population>
        <group_list>
          <group group_id="O1">
            <title>Fosaprepitant Including Placebo</title>
            <description>Fosaprepitant (EMEND™) for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy.Oral Placebo 125 mg given 1 hour prior to infusion of chemotherapy on day 1 and oral Placebo 80 mg on day 2 and day 3.Patient will receive standard pre-medications on day 1
Aprepitant (EMEND™) is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3
fosaprepitant including placebo: Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications</description>
          </group>
          <group group_id="O2">
            <title>Aprepitant Including Placebo</title>
            <description>Aprepitant (EMEND™) is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) with Intravenous Placebo and 80 mg orally once daily in the morning on Days 2 and 3 with Placebo Intravenously on day 1. patient will receive standard pre-medications on day 1.
aprepitant including placebo: Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Complete Response Rate</title>
          <description>no emetic episodes or rescue therapy following the initiation of chemotherapy</description>
          <population>Study participants included adult, female patients with a histologically confirmed, newly diagnosed gynecologic cancer (e.g., epithelial ovarian, fallopian tube, primary peritoneal cancer or uterine cancer).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were reviewed and collected 28 days after treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fosaprepitant and Placebo</title>
          <description>Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy.Oral Placebo 125 mg given 1 hour prior to infusion of chemotherapy on day 1 and oral Placebo 80 mg on day 2 and day 3.Patient will receive standard pre-medications on day 1</description>
        </group>
        <group group_id="E2">
          <title>Aprepitant and Placebo</title>
          <description>Aprepitant is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) with Intravenous Placebo on day 1 and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications on day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John P. Micha, M.D.</name_or_title>
      <organization>Gynecologic Oncology Associates</organization>
      <phone>949-642-5165</phone>
      <email>Research@gynoncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

